Cancer Research Experience for Undergraduates (CREU)

Through the University of Colorado Cancer Center's Cancer Research Experience for Undergraduates (CREU), every summer, selected college undergraduate fellows spend ten weeks in our laboratories at the University of Colorado Anschutz Medical Campus. An R25CA240122 grant and the University of Colorado Cancer Center support the CREU program.

The goal of the program is to engage scientific curiosity in the next generation of scientists, challenging qualified college undergraduates to consider a cancer-related career in the future.

Additional participants in the American Cancer Society’s (ACS) Diversity in Cancer Research (DICR) Internship program will form a cohort with fellows participating in CREU. For more information on the DICR Internship program, which will use the same application as CREU, click here.

Important Dates

November 1, 2024 – February 3, 2025: Program application open

February 3, 2025: Final application deadline (11:59 pm MT)

May 27 – August 1, 2025: CREU/DICR Program

Applications are closed.

Information Session

Watch our recorded information session to learn more about the CREU and DICR summer programs and the 2025 application.

Watch Here

What to know about the Cancer Research Experience for Undergraduates

Fellows work full-time for approximately ten weeks during the summer.
Fellows may not combine their research work with other significant work commitments or daytime class work.
Stipends are paid in biweekly installments through direct deposit as fellows complete their program requirements.
A housing allowance may be provided on an as-needed basis. The CREU/DICR team will send housing options and information to accepted fellows.

Fellowships are open to:

Students currently enrolled at an undergraduate institution – including seniors.
Students who are able to devote 40 hours per week to this program.
U.S. citizens, permanent residents, or a Deferred Action for Childhood Arrivals (DACA) recipients.
Individuals from all backgrounds who seek to expand knowledge, representation, perspectives, and/or experiences in the biomedical sciences.

Fellows must commit to completing program requirements. If you are selected as a fellow in either program (CREU or DICR), you must sign a Student Agreement committing to these requirements:

Orientation

Orientation will be held on the first day of the program. This one-hour meeting is mandatory for all fellows (unless prior arrangements have been made). We will cover program requirements, training requirements, stipends, and more.

Goals and Objectives

With the help of your mentor, you will write a two to three-page, double-spaced report describing the goals of your research project. The report is due within ten (10) days of your start date. Your mentor will also sign the report.

Twice-weekly Lectures

All fellows are required to attend twice-weekly lectures on various topics related to cancer research. Presenters will include mentors and faculty members. Topics will range from discussions on different cancer types and health disparities to effective research presentations. Attendance will be taken at these lectures.

Clinical/Translational Workshops

These half-day workshops feature speakers from faculty and biotechnology companies on the CU Anschutz campus. These workshops aim to enhance the fellows’ research experience. They capitalize on the unique strengths and cancer training opportunities at CU Anschutz in personalized medicine/ molecular diagnostics, cancer genomics /bioinformatics, and experimental therapeutics/emerging technologies. Attending at least two of these workshops is required.

Career Mentoring

These informal discussions will be held during the ten weeks. Presenters and panel members will be drawn from faculty, postdoc trainees, and professional scientists in the community. Topics will include academic career trajectories, biotech/pharmaceuticals careers, life/work balance, and others as suggested by CREU/DICR participants. An informal Q&A session will follow each discussion.

Poster Session

All fellows will participate in the annual poster session on the last day of the program.

When you apply to be a CREU fellow/DICR intern, you will select four mentors you would like to work with and note them on your application. We make every effort to assign you to your first choice, but we may make alternative assignments based on mentor availability.

Projects are performed on the Anschutz Medical Campus.

Click on a mentor’s name to view their faculty profile or lab page.

*Projects are subject to change at any time. They are likely representative of what that person’s lab is doing, but not a guarantee of the actual project you will be performing.

Name	Department/School	Research Interests
Michael Alberti, MD-PhD	Department of Pathology - School of Medicine	Genetic and molecular basis of splicing factor gene mutations in clonal hematopoiesis and myeloid malignancies.
Benjamin Bitler, PhD	Department of Obstetrics and Gynecology – School of Medicine	Disease progression and metastasis in ovarian cancer.
Andrea Bonetto, PhD	Department of Pathology - School of Medicine	Bone-liver-muscle interactions in colorectal cancer.
Gina Bouchard, PhD* *Not listed in the application; note Dr. Bouchard is a preferred mentor in the “additional comments” section at the end of the application.	Department of Pharmaceutical Sciences – School of Pharmacy and Pharmaceutical Sciences	To investigate metabolic reprogramming in tumor-stroma interactions through the O-glycoproteome, identify new targets to overcome radioresistance, and bridge the gap between patient-derived in vitro models and human pathological samples to understand the spatiotemporal dynamics of tumor compartments under treatment, ultimately identifying resistant spatial patterns.
Cecilia Caino, PhD	Department of Pharmacology – School of Medicine	Role of mitochondria biology in metastatic breast and prostate cancers.
Akshay Chauhan, MD	Department of Surgery, Division of GI, Trauma, and Endocrine Surgery (GITES) – School of Medicine	Effectiveness of monoclonal antibody Miltuximab in targeting a protein biomarker for aggressive, advanced esophageal cancer.
Diana Cittelly, PhD	Department of Pathology - School of Medicine	Activation of transcription factors in breast cancer cells when interacting with cells within the brain tumor microenvironment; formation of pseudosynapsis between cancer cells and neurons in brain metastases.
Zachary Clayton, PhD	Division of Geriatric Medicine – School of Medicine	We will be performing preclinical studies in mice to assess the adverse effects of cancer and chemotherapy treatment on the cardiovascular system and determining how high-intensity interval training may mitigate this response.
Kasey Couts, PhD	Division of Medical Oncology – School of Medicine	The main focus of our current research is to understand and improve anti-tumor immunity in rare melanomas, particularly mucosal melanoma. We are studying signaling pathways in tumors that are critical for response to immunotherapy, and we are trying to determine the factors that influence these pathways such as tumor epigenetics and the microbiome.
Eduardo Davila, PhD	Division of Medical Oncology – School of Medicine	Generation of potent and long-lasting tumor-specific T cell responses
James DeGregori, PhD	Department of Biochemistry and Molecular Genetics - School of Medicine	Understanding how carcinogenic conditions promote cancer evolution and discovering pathway dependencies in cancers that can be exploited therapeutically.
Elan Eisenmesser, PhD	Department of Biochemistry and Molecular Genetics - School of Medicine	We work on a range of enzymes involved in many cancers, such as metabolic enzymes and proteases. We have new projects that have begun to figure out mechanisms of granzyme activation, which may be attractive.
Patricia Ernst, PhD	Department of Pharmacology – School of Medicine	The mechanisms that control the balance between self-renewing and differentiating hematopoietic stem cell (HSC) divisions are one major interest of our group. Since these processes are often deregulated in leukemia, we study molecular pathways in both normal and leukemic cells to better understand how proliferation, self-renewal and differentiation are disrupted by leukemia-associated fusion oncogenes.
Joaquin Espinosa, PhD	Department of Pharmacology – School of Medicine	Understanding how gene networks control cell behavior in homeostasis and human disease.
Xiying Fan, PhD	Department of Dermatology – School of Medicine	We anticipate working on projects focused on cutaneous squamous cell carcinoma (cSCC) research, especially invasive cSCC. Specifically, we will explore the molecular mechanisms underlying the progression of invasive cSCC, with an emphasis on identifying key factors and signaling pathways involved in tumor invasion and metastasis.
Daysha Ferrer Torres, PhD* *Not listed in the application; note Dr. Ferrer Torres is a preferred mentor in the “additional comments” section at the end of the application.	Division of Gastroenterology and Hepatology – School of Medicine	The Ferrer-Torres Lab studies how the esophagus repairs itself after injury and how these processes differ across racial and genetic backgrounds, focusing on conditions like GERD, Barrett’s esophagus, and esophageal cancer. The lab explores the role of the protective enzyme GSTT2 and has developed advanced organoid models that mimic esophageal tissue, including both epithelial and mesenchymal layers, to study development and repair. By using these tools, the lab aims to discover new treatments and improve personalized care for diverse populations.
Heide Ford, PhD	Department of Pharmacology – School of Medicine	My laboratory works on the parallels between normal development and tumor progression/metastasis. We study how cellular plasticity, mediated by alterations in transcription or translation, can allow cancer cells to survive and colonize secondary sites. We work in multiple tumor types, including breast cancer, brain tumors, and pediatric sarcomas.
Mayumi Fujita, MD-PhD	Department of Dermatology – School of Medicine	Investigating biological roles and molecular regulations of 1) IL-37 in adaptive immunity, 2) IL-1b, inflammasomes, and autoinflammation in human melanoma, 3) genotoxic metabolites in melanocytes and skin cells, and 4) intra-tumoral heterogeneity and plasticity in melanoma.
Michael Graner, PhD	Department of Neurosurgery – School of Medicine	Understanding tumor/host immune responses in immune suppression and immunotherapy development.
Kirk Hansen, PhD	Department of Biochemistry and Molecular Genetics - School of Medicine	One of our main focuses is improving characterization of tissue extracellular matrices (ECM). We have been refining traditional biochemical extraction and digestion methods to improve proteomic coverage of insoluble and crosslinked proteins of the ECM. These methods are being used to obtain a more detailed view of tissue remodeling in wound healing, aging, cancer and fibrotic diseases in general.
Masanori Hayashi, MD	Department of Pediatrics, Division of Hematology, Oncology & Bone Marrow Transplantation – School of Medicine	Research centers on innovative approaches to understanding and treating pediatric sarcomas, particularly osteosarcoma and Ewing sarcoma.
Lynn Heasley, PhD	Department of Craniofacial Biology – School of Dental Medicine	Our lab studies the role of the tumor microenvironment including diverse immune cells in regulating the response of murine models of lung adenocarcinoma to oncogene-targeted therapeutics.
Curtis Henry, PhD	Department of Immunology & Microbiology - School of Medicine	The student will be attempting to define how aging or obesity impacts anti-tumor immunity and the efficacy of immunotherapies.
Melanie Joy, PhD	Skaggs School of Pharmacy and Pharmaceutical Sciences	A goal of this research program is focused on circumventing kidney injury and related morbidity and mortality due to medications, especially those pertaining to cancer treatments. The research in this area incorporates in vitro and in vivo studies. Specific areas of emphasis are 1) mitigation of kidney injury, 2) role of drug metabolism and transport in nephrotoxicity, 3) role of pharmacogenomics in kidney injury due to drugs.
Miria Kano, PhD	Department of Community and Behavioral Health – School of Public Health	Dr. Kano is a medical anthropologist whose cancer health disparities research focuses on healthcare access and delivery for cancer patients and caregivers minoritized as sexual and gender minority individuals, those who identify as lesbian, gay, bisexual, transgender, and queer. Kano's research utilizes intersectional approaches to better understand how interrelated factors such as race/ethnicity, geography, poverty, and/or other social determinants of health may inform intervention development. As a secondary focus, Dr. Kano's research involves the design and implementation of equity education and training for cancer researchers and oncology providers.
Aaron Johnson, PhD	Department of Biochemistry and Molecular Genetics - School of Medicine	The formation and regulation of chromatin domains and their roles in epigenetic genome regulation.
Laurel Lenz, PhD	Department of Immunology & Microbiology - School of Medicine	We have identified proteins produced by pathogenic, commensal, or probiotic bacteria that modulate immune responses. One of these proteins has shown promise in activation of anti-tumor immune responses in murine models. Some appear to dampen inflammatory responses. We are working to identify the mechanisms through which these proteins exert their effects so they (or the bacteria that produce them) can be better harnessed to treat or prevent cancers and other chronic diseases.
Traci Lyons, PhD	Division of Medical Oncology - School of Medicine	Mechanisms of semaphorin 7a and lymphatic mediated metastasis of breast cancer utilizing mouse models to investigate developmentally regulated programs of inflammation and lymphangiogenesis.
Carlo Marchetti, PhD	Division of Infectious Diseases – School of Medicine	Focusing on the NLRP3 inflammasome's role in cancer and inflammatory diseases, exploring its mechanisms and potential therapeutic strategies. Key findings highlight how NLRP3 activation influences tumor microenvironments, mediates immune responses, and interacts with pathways like STAT3 in melanoma and breast cancer.
Siddhartha Mitra, PhD	Department of Pediatrics, Division of Hematology, Oncology & Bone Marrow Transplantation – School of Medicine	Focusing on innovative therapeutic strategies and tumor biology in pediatric brain tumors, including MYC-driven medulloblastoma and childhood ependymoma. Investigating the effects of Tacedinaline (CI-994), a class I HDAC inhibitor, which targets tumor growth and leptomeningeal dissemination in medulloblastoma, enhancing susceptibility to anti-CD47-induced macrophage phagocytosis through NF-kB-driven inflammation.
Joe Nassour, PhD	Department of Biochemistry and Molecular Genetics - School of Medicine	Our laboratory studies various aspects of telomere biology, with a specific focus on understanding how the shortening of telomeres during replicative aging creates barriers to cell proliferation and restricts the development of cancer. Our research entails a combination of advanced techniques in cell biology, molecular biology, and single-cell multiomics to explore the interplay between telomere function, innate immune signaling, and autophagy, and how these pathways work together to suppress the early stages of tumor development.
Raphael Nemenoff, PhD	Division of Renal Diseases and Hypertension – School of Medicine	Using an orthotopic mouse model of lung cancer to understand the cross-talk between cancer cells and the tumor microenvironment that mediates response to immunotherapy.
Chad Pearson, PhD	Department of Cell & Developmental Biology – School of Medicine	Mechanisms of cytoskeleton disorganization in cancer. We study why centrosomes are commonly dysregulated in breast cancer cells and how this might be corrected.
Todd Pitts, PhD	Division of Medical Oncology - School of Medicine	Finding rational combination partners for molecularly-targeted anticancer and immunotherapy agents. With a special interest in predictive biomarker and resistance mechanisms using correlative biological assays for early phase clinical trials.
Rytis Prekeris, PhD	Department of Cell & Developmental Biology - School of Medicine	My lab works on molecular mechanism regulating breast cancer cell migration and invasion.
Srinivas Ramachandran, PhD	Department of Biochemistry and Molecular Genetics - School of Medicine	Fundamental mechanisms that shape chromatin landscapes by mapping chromatin structure at high temporal and spatial resolution using new experimental and/or computational methods.
Jennifer Richer, PhD	Department of Pathology - School of Medicine	Breast cancer studies of hormone receptor action, tumor immunology and tumor metabolism that affect disease progression.
Mercedes Rincon, PhD	Department of Immunology and Microbiology – School of Medicine	Investigating critical pathways in immunology, cancer, and metabolism, focusing on the roles of p38 MAPK, GSK3β, IL-6, and MCJ in T cell development and function.
Abigail Rolbiecki, PhD	Department of Family Medicine – School of Medicine	Palliative and supportive care. Pain management. Caregiver interventions.
Rebecca Schweppe, PhD	Division of Endocrinology, Metabolism, and Diabetes – School of Medicine	Our lab focuses on kinase signaling in thyroid cancer. Our goal is to understand mechanisms of resistance to targeted therapies to develop new more effective therapies to improve patient outcomes.
Carol Sartorius, PhD	Department of Pathology - School of Medicine	Understanding the regulation of HR+ breast cancer heterogeneity during endocrine resistance, the mechanisms of advanced ER+ breast cancer metastasis, nuclear receptor regulation of RNA polymerase III, and altered breast cancer cell metabolism with hormones and endocrine resistance.
Natalie Serkova, PhD	Department of Radiology – School of Medicine	To characterize tumor habitat (cellular and molecular phenotype, tumor aggressiveness, and micro-environment) in mouse models of pediatric and adult brain tumor models using state-of-the-art non-invasive imaging (MRI, CT, PET/CT, optical imaging).
Dan Sherbenou, MD-PhD	Division of Hematology – School of Medicine	Therapeutic optimization for multiple myeloma, especially for patients with drug-resistant and advanced disease to develop novel immunotherapies to myeloma, especially antibody-based therapies.
Michael Sikora, PhD	Department of Pathology - School of Medicine	Response and resistance to anti-estrogen therapies in lobular breast cancer.
Jill Slansky, PhD	Department of Immunology and Microbiology – School of Medicine	Using a colon cancer animal model to identify “mimotope” peptides (mimics of epitopes) with improved antitumor immunity.
Jamie Studts, PhD	Division of Medical Oncology - School of Medicine	Cancer prevention and control--behavioral science with a focus on lung cancer, including screening and survivorship.
Meredith Tennis, PhD	Division of Pulmonary Sciences and Critical Care – School of Medicine	The Tennis lab is focused on lung cancer premalignancy and prevention, conducting experiments using cell and mouse models and human clinical trial samples.
Sarah Tevis, MD	Department of Surgery, Division of Surgical Oncology – School of Medicine	Understanding the enduring physical and psychological side effects of breast cancer treatment, with the goal of improving the efficiency of care, patient safety, and patient outcomes after surgery for breast disease.
Arianne Theiss, PhD	Division of Gastroenterology and Hepatology – School of Medicine	Role and mechanism of mitochondrial signaling in intestinal epithelial cells in gastrointestinal diseases, specifically inflammatory bowel diseases (IBD), colitis-associated cancer, and colorectal tumorigenesis.
Richard Tobin, PhD	Department of Surgery, Division of Surgical Oncology – School of Medicine	My lab is interested in understanding the factors that lead to effective anti-tumor immunity. We have ongoing projects focusing on the role of unconventional T cells, immunosuppressive myeloid cells, and neo-adjuvant therapies in melanoma immunity.
Linda van Dyk, PhD	Department of Immunology and Microbiology – School of Medicine	We study cancer-associated viruses, particularly interactions between virus and host and host immunity to chronic infection.
Rajeev Vibhakar, MD-PhD	Department of Pediatrics, Division of Hematology, Oncology & Bone Marrow Transplantation – School of Medicine	Focusing on understanding and targeting pediatric brain tumors, particularly high-grade gliomas and medulloblastomas. We explore the complex interactions between tumor and immune cell types, revealing that these interactions contribute to the heterogeneous phenotypes observed in pediatric high-grade glioma.
Beat Vögeli, PhD	Department of Biochemistry and Molecular Genetics - School of Medicine	Targeting macromolecules for cancer treatment at atomic resolution using NMR and further biophysical tools.
Margaret Wierman, MD	Division of Endocrinology, Metabolism, and Diabetes – School of Medicine	Research in our lab focuses on understanding the mechanisms of pituitary tumorigenesis and adrenocortical cancer using cell and animal models towards finding new treatments for our patients.
Christian Young, PhD	Department of Pathology - School of Medicine	Identifying and targeting critical molecular mediators of transformation and metastasis in Head and neck squamous cell carcinoma (HNSCC).
Ning Zhao, PhD	Department of Biochemistry and Molecular Genetics - School of Medicine	My lab studies the regulation of translation and co-translational folding in health and diseases. We apply a state-of-the-art imaging technology to direct visualize translation and co-translational folding with high spatiotemporal resolution in live cells.

Meet Our Past Fellows

Esha Chopra, a 2024 CREU student, named a 2025 NSF Graduate Research Fellowship Program (GRFP) fellow.

CREU 2024 alumna, Esha Chopra, has been awarded a prestigious NSF GRFP fellowship to pursue her graduate studies in biomedical engineering at the Rensselaer Polytechnic Institute. GRFP recognizes and supports outstanding students early in their careers who are pursuing research-based master’s and doctoral degrees in science, technology, engineering, and mathematics (STEM) or in STEM education at accredited U.S. institutions. The five-year fellowship provides three years of financial support, inclusive of an annual stipend.

Congratulations, Esha, on this tremendous achievement!

CREU Program Provides Pathways to Research Success for Undergraduates, with Insights from Khoa Nguyễn

The Cancer Research Experience for Undergraduates (CREU) program is a transformative initiative designed to provide students, especially those from first-generation college or socioeconomically disadvantaged backgrounds, with opportunities to gain hands-on experience in scientific research. By offering financial support, mentorship, and educational resources, the program allows students to focus entirely on their research pursuits without the burden of financial concerns.

Khoa Nguyễn, an MD/MBA candidate at the University of Colorado Anschutz School of Medicine, is one of the many students whose academic journey has been shaped by CREU. Nguyễn first joined the program before the COVID-19 pandemic and received additional funding in 2021 for in-person research activities. Reflecting on his experience, Nguyễn highlighted the importance of mentorship, which he believes was crucial for his growth. CREU not only provided him with professional skills, such as poster building and abstract submission, but also empowered him with opportunities to engage in research and present his findings, tools essential for furthering a career in science.

Nguyễn’s CREU research, under the mentorship of Michael Graner, PhD, primarily focused on neurosurgery, particularly brain tumors. His work centered on chordomas—rare tumors of the spine that can metastasize to the skull base. His research on exosomal interactions within chordoma cells, an area largely unexplored, aimed to understand how exosomes—small vesicles that carry genetic material and proteins—impact osteoblasts and the tumor microenvironment. This groundbreaking work has the potential to uncover new therapeutic pathways for rare tumor types. Looking forward, Nguyễn postulated, “I hope the findings from our research serve as a fundamental cornerstone to further motivate other researchers to continue exploring the signaling pathways of chordoma tumors and their exosomal effects, with the goal of advancing therapeutic options for this challenging pathology.”

Since his time with CREU, Nguyễn’s experience in medicine has inspired him to pursue a clinical career in plastic and reconstructive surgery. He is also involved in research focused on improving breast cancer reconstruction techniques, specifically salvage reconstruction methods post-mastectomy, to enhance patient outcomes using natural tissue. He notes, “CREU gave me the experience and skills to translate my research abilities towards any field of interest, so that I can continue to advance healthcare for my patients. I am beyond grateful to Dr. Graner and the program for shaping my path.”

In addition to his medical training, Nguyễn is pursuing an MBA through a dual-degree program to complement his clinical expertise with strategic decision-making skills in healthcare. He is passionate about advocating for underprivileged students and breaking down socioeconomic barriers in medical education, ensuring equitable access to research opportunities for all.

The CREU program continues to be a vital resource for undergraduates interested in cancer research. With its ongoing commitment to inclusivity, mentorship, and professional development, the program encourages students from diverse backgrounds to apply. As it fosters the next generation of researchers, CREU remains dedicated to providing meaningful research experiences that can lead to significant advancements in healthcare.

CREU 2024 Alumni Rank in Top 15% for Cancer Biology Presentations at Fall Conference

CREU 2024 alumni Troy Sensano (University of Hawai‘i at Mānoa), Reina Saldivar (University of Texas at San Antonio), and Alondra Rodriguez (University of Texas at El Paso) were recognized for their Outstanding Undergraduate Poster Presentations in Cancer Biology at the 2024 Annual Biomedical Research Conference for Minoritized Scientists (ABRCMS) in Pittsburgh, PA. Their presentations placed them in the top 15% of students presenting in the Cancer Biology category at the conference.

Congratulations to Troy, Reina, and Alondra, and best wishes to them and their 2024 cohort in all their future endeavors!

Elijah Johnson, a 2022 CREU Fellow, came to the CU Cancer Center to research the mutation that makes him more likely to develop cancer.

Growing up in Windsor, Colorado, Elijah Johnson thought he would grow up to be a professional musician. He never considered a career as a biomedical researcher. But that all changed when his mother was diagnosed with Li-Fraumeni Syndrome (LFS), a rare genetic mutation that increases the risk of cancer.

→ Read Elijah's Story Here.

Accomplishments

Do you have an accomplishments you'd like to share? Let us know at the link below!

CREU/DICR Accomplishments Form

Tools & Resources

CU Campuses

CU Anschutz Medical Campus

University of Colorado Cancer Center

School of Medicine

Cancer Research Experience for Undergraduates (CREU)

Important Dates

Applications are closed.

Information Session

Watch Here

What to know about the Cancer Research Experience for Undergraduates

Fellowships are open to:

Orientation

Goals and Objectives

Twice-weekly Lectures

Clinical/Translational Workshops

Career Mentoring

Poster Session

Questions? Contact us for more information:

Meet Our Past Fellows

Esha Chopra, a 2024 CREU student, named a 2025 NSF Graduate Research Fellowship Program (GRFP) fellow.

CREU Program Provides Pathways to Research Success for Undergraduates, with Insights from Khoa Nguyễn

CREU 2024 Alumni Rank in Top 15% for Cancer Biology Presentations at Fall Conference

Elijah Johnson, a 2022 CREU Fellow, came to the CU Cancer Center to research the mutation that makes him more likely to develop cancer.

Accomplishments

Cancer Center (SOM)

Cancer Research Experience for Undergraduates (CREU)

Important Dates

Applications are closed.

Information Session

Watch Here

Program Information

Program Requirements

Program Mentors

Contact Us

Meet Our Past Fellows

Esha Chopra, a 2024 CREU student, named a 2025 NSF Graduate Research Fellowship Program (GRFP) fellow.

CREU Program Provides Pathways to Research Success for Undergraduates, with Insights from Khoa Nguyễn

CREU 2024 Alumni Rank in Top 15% for Cancer Biology Presentations at Fall Conference

Elijah Johnson, a 2022 CREU Fellow, came to the CU Cancer Center to research the mutation that makes him more likely to develop cancer.

Accomplishments

Cancer Center (SOM)